ERBB2 and breast cancer: The study was comparing efficacy of T-DM1 vs. trastuzumab alone in 1486 early-stage HER2+ breast cancer patients with residual invasive disease after surgery or neoadjuvant systemic therapy (NAST) with taxane plus trastuzumab.